Windlas Biotech (WINDLAS) Fundamentals 2026 — P/E 27.5x, Revenue Analysis | SniperIQ
Windlas Biotech (WINDLAS) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹1,841 Crore, trading at ₹870.00 on the NSE. This SniperIQ fundamentals page covers Windlas Biotech's valuation (P/E 27.5x, P/B 3.2x), profitability (net margin 7.4%), revenue (₹904 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Windlas Biotech's market cap?
Windlas Biotech (WINDLAS) has a market capitalization of approximately ₹1,841 Crore, trading at ₹870.00 on the NSE. Market cap moves with the live share price.
What is Windlas Biotech's P/E ratio?
Windlas Biotech's trailing twelve-month P/E ratio is 27.5x, with a price-to-book (P/B) of 3.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Windlas Biotech?
Windlas Biotech runs a net profit margin of 7.4%, a gross margin of 27.4%, and an operating margin of 8.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Windlas Biotech generate?
Windlas Biotech reported revenue of ₹904 Crore for fiscal year 2026, with net income of ₹66 Crore and earnings per share (EPS) of 31.6. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Windlas Biotech pay a dividend?
Windlas Biotech offers a trailing dividend yield of about 0.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Windlas Biotech financially healthy?
Windlas Biotech carries a debt-to-equity ratio of 0.06x and a current ratio of 1.95x, with a market beta of 0.27. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Windlas Biotech a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Windlas Biotech (WINDLAS) the key facts are: market cap ₹1,841 Crore, P/E 27.5x, revenue ₹904 Crore, 52-week range 697.4-1097.9. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Windlas Biotech's full fundamentals live
Get Windlas Biotech's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.